fluticasone furoate/umeclidinium/vilanterol

Details

Files
Generic Name:
fluticasone furoate umeclidinium vilanterol
Project Status:
Complete
Therapeutic Area:
Chronic obstructive pulmonary disease (COPD)
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Trelegy Ellipta
Project Line:
Reimbursement Review
Project Number:
SR0562-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the long-term, once daily, maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, where the following clinical criteria are met: - Moderate to severe COPD as defined by spirometry; and - At risk of exacerbations despite a long-acting bronchodilator (LAMA or LABA); or - Symptomatic or at risk of exacerbations despite a LAMA/LABA or ICS/LABA; or - Currently on a LAMA/ICS/LABA.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Chronic obstructive pulmonary disease (COPD)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input posted January 31, 2018
Patient group input closed March 22, 2018
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groups April 03, 2018
Patient group comments on input summary closed April 10, 2018
Clarification:

- Patient input summary feedback received

Submission received March 01, 2018
Submission accepted for review March 15, 2018
Review initiated March 16, 2018
Draft CDR review report(s) sent to applicant June 04, 2018
Comments from applicant on draft CDR review report(s) received June 13, 2018
Redaction requests from applicant on draft CDR review report(s) received June 20, 2018
CDR review team's comments on draft CDR review report(s) sent to applicant July 06, 2018
Canadian Drug Expert Committee (CDEC) meeting July 18, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans August 01, 2018
Embargo period ended and validation of redacted CDR review report(s) received August 16, 2018
CDEC Final Recommendation issued to applicant and drug plans August 23, 2018
CDEC Final Recommendation posted August 27, 2018
Final CDR review report(s) and patient input posted September 18, 2018